Drug updated on 11/13/2023
|Tablet (oral; 200 mg, 250 mg, 300 mg)
|Poly (ADP-ribose) polymerase (PARP) inhibitors
| Ongoing and
- For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- For the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
Product Monograph / Prescribing Information
|Rubraca (rucaparib) Prescribing Information.
|Clovis Oncology, Inc., Boulder, CO
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
|Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
|Annals of Oncology
|Guidelines for management of treatment-emergent adverse events during rucaparib treatment of patients with metastatic castration-resistant prostate cancer.
|Cancer Management and Research
|PARP inhibitors in the management of ovarian cancer: ASCO guideline.
|Journal of Clinical Oncology